Bio-Me Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
19
- Latest Deal Type
-
2ndary - Private
- Investors
-
6
Bio-Me General Information
Description
Developer of a microbiome research platform designed to perform microbiome analysis. The company's platform combines fecal samples from large population-wide biobanks with proprietary gut microbiome analysis and creates a database that uses machine learning technology to predict optimal options for both treatment and prevention of disease, enabling pharmaceutical businesses to make precision medicine and personalized nutrition.
Contact Information
Website
www.bio-me.comCorporate Office
- Oslo Science Park
- Gaustadalléen 21
- 0349 Oslo
- Norway
Corporate Office
- Oslo Science Park
- Gaustadalléen 21
- 0349 Oslo
- Norway
Bio-Me Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Secondary Transaction - Private | 01-Feb-2026 | Completed | Clinical Trials - General | |||
| 12. Accelerator/Incubator | 02-Oct-2024 | Completed | Clinical Trials - General | |||
| 11. Accelerator/Incubator | Completed | Clinical Trials - General | ||||
| 10. Later Stage VC | 10-Jun-2021 | Completed | Clinical Trials - General | |||
| 9. Grant | 21-Apr-2020 | Completed | Clinical Trials - General | |||
| 8. Early Stage VC | 01-Apr-2020 | Completed | Clinical Trials - General | |||
| 7. Seed Round | 20-Nov-2018 | Completed | Clinical Trials - General | |||
| 6. Seed Round | 27-Sep-2018 | Completed | Clinical Trials - General | |||
| 5. Seed Round | 27-Sep-2017 | Completed | Clinical Trials - General | |||
| 4. Seed Round | 21-Apr-2017 | Completed | Clinical Trials - General |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Bio-Me Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Bio-Me Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Bio-Me Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ShareLab Incubator | Accelerator/Incubator | |||
| Strahl Capital | PE/Buyout | Minority | ||
| Tjuvholmen Ventures | Venture Capital | Minority | ||
| TRK Group | Venture Capital | Minority | ||
| The Research Council of Norway | Government |
Bio-Me FAQs
-
When was Bio-Me founded?
Bio-Me was founded in 2016.
-
Where is Bio-Me headquartered?
Bio-Me is headquartered in Oslo, Norway.
-
What is the size of Bio-Me?
Bio-Me has 19 total employees.
-
What industry is Bio-Me in?
Bio-Me’s primary industry is Other Healthcare Technology Systems.
-
Is Bio-Me a private or public company?
Bio-Me is a Private company.
-
What is Bio-Me’s current revenue?
The current revenue for Bio-Me is .
-
How much funding has Bio-Me raised over time?
Bio-Me has raised $1.52M.
-
Who are Bio-Me’s investors?
ShareLab Incubator, Strahl Capital, Tjuvholmen Ventures, TRK Group, and The Research Council of Norway are 5 of 6 investors who have invested in Bio-Me.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
